V8 Peptides — Engineered Performance
Research Library
IGF-1 LR3 vs Des(1-3) IGF-1: Choosing an Assay Analog
IGF-1 LR3Comparison

IGF-1 LR3 vs Des(1-3) IGF-1: Choosing an Assay Analog

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What separates IGF-1 LR3 from des(1-3) IGF-1? Both are engineered forms of IGF-1 that bind IGF-binding proteins (IGFBPs) poorly, which is why both look more potent than native IGF-1 in cell cultures that contain IGFBPs. Des(1-3) IGF-1 is the native sequence with the first three residues (Gly-Pro-Glu) removed, giving a 67-residue peptide. IGF-1 LR3 keeps the full chain, replaces Glu3 with Arg and adds a 13-residue N-terminal extension, giving 83 residues. The practical question is not which one is “stronger” but which one fits the assay: medium composition, the IGFBPs present, and whether a native-like control is needed. Both are supplied here for laboratory research use only.

Searches for “IGF-1 LR3 vs IGF-1 des” usually come from someone planning a cell-culture or receptor-signaling experiment who needs to pick one analog. This article takes the decision view: what each modification does to IGFBP interaction, what the published papers measured, and how that translates into controls and readouts. A head-to-head structural summary already exists in the LR3 vs Des research comparison; this piece focuses on assay selection. The V8 IGF-1 LR3 product page lists the LR3 analog, and the IGF-1 LR3 research overview covers the compound itself.

Two ways to evade IGF-binding proteins

IGF-1 in culture does not act alone. Six IGFBPs, made by many cell types and present in serum, bind IGF-1 with high affinity. Reviews of the family describe how IGFBPs sequester IGFs away from the type 1 IGF receptor and so can inhibit IGF-stimulated mitogenesis, differentiation and survival, while in some contexts matrix association can concentrate IGFs near the receptor instead (Firth and Baxter 2002; Baxter 2000). A cell culture therefore contains a competing binder whose amount varies with cell type, density and medium. An analog that binds IGFBPs poorly will give a more reproducible signal in that setting.

Two different chemical strategies reach that goal. Removing the N-terminal tripeptide produces des(1-3) IGF-1. Ballard and colleagues compared native and destripeptide IGF-1 in L6 myoblasts and reported that the truncated form was roughly seven times more potent in a protein-synthesis bioassay without a matching rise in its ability to compete for IGF-1 binding to the cells (Ballard 1987). That pattern, higher bioactivity without higher receptor affinity, fits the idea that the gain comes from reduced interference rather than tighter receptor binding. A later study found that IGFBPs inhibited the activity of IGF-1 and IGF-2 but not of des(1-3) IGF-1 (Ross 1989).

The second strategy is the Long R3 design. Francis and colleagues expressed IGF-1 fusion analogues in E. coli in which the first 11 residues of methionyl porcine growth hormone, plus Val-Asn, precede the IGF-1 sequence, with Glu3 replaced by Arg in the “Long [Arg3]” form (Francis 1992). The result is an 83-residue peptide of roughly 9.1 kDa, as listed on the product page. The extension also seems to help the denatured protein fold correctly during production. Earlier work had already shown that structural analogs of IGF-1 with reduced affinity for serum binding proteins could be made (Bayne 1988), so the underlying principle is long established.

Side-by-side: what actually differs

PropertyNative IGF-1Des(1-3) IGF-1IGF-1 LR3
Length70 residues67 residues (Gly-Pro-Glu removed)83 residues (13-residue N-terminal extension)
Position 3GluAbsentArg
Approximate massabout 7.6 kDaabout 7.3 kDaabout 9.1 kDa (product page)
IGFBP interactionHigh-affinity bindingReduced; IGFBPs did not inhibit it in the cited workReduced (design goal of Glu3Arg plus extension)
Receptor bindingReferenceNot increased in the L6 comparisonDepends on the assay; measure it rather than assume
Typical use in culturePhysiological referenceSerum-containing or conditioned mediaSerum-free and defined media
Source hereNot listedNot listedListed on the product page, 1 mg

The mass figures for the native and truncated forms follow from the residue counts and are approximate; the LR3 figure is the one stated on the product page. Read the table as a map of design logic rather than a potency ranking, because potency numbers depend on the cell line, the IGFBP load and the readout.

When each analog fits the experiment

Start from the medium, not the peptide. A defined serum-free medium has few IGFBPs, so native IGF-1 may already behave predictably and an engineered analog adds a variable you do not need. A serum-containing medium, or a conditioned medium from cells that secrete IGFBPs, is where the analogs separate from native IGF-1 most clearly. Reviews of IGFBP function note that these proteins are cell-type specific and regulated by proteolysis and matrix association, so the binding landscape can shift during a single experiment (Firth and Baxter 2002).

Then decide what the readout is meant to say. If the aim is to test IGF-1 receptor signaling downstream of the receptor, an IGFBP-evading analog removes one source of noise. If the aim is to study how IGFBPs shape IGF action, an analog that ignores them is the wrong tool, or at best a useful contrast: run native IGF-1 and the analog side by side and let the difference between them report the IGFBP contribution. Mutagenesis work on IGFBP structure and function supports this logic, because it relies on comparing variants in one test system to assign function to a domain (Clemmons 2001).

Experimental questionReasonable choiceControl to include
Receptor signaling in defined mediumNative IGF-1 or an analogBoth, at matched molar concentration
Signaling in serum-containing mediumAn IGFBP-evading analogNative IGF-1 to expose the IGFBP effect
Role of a specific IGFBPNative IGF-1 plus the IGFBPAnalog as an IGFBP-insensitive comparator
Reproducibility across cell linesAn IGFBP-evading analogMeasure IGFBP output of each line
Dose-response shapeWhichever matches the downstream claimVehicle and an irrelevant peptide control

Concentration arithmetic without a table

Because the two analogs differ in mass, equal weights are not equal molar amounts. Convert before comparing. Moles equal mass divided by molecular weight, and molar concentration equals moles divided by volume: n = m / MW and C = n / V. For a given stock concentration, the amount of analog needed for a target molar concentration in a well is Cstock × Vstock = Cfinal × Vfinal. The reconstitution calculator does the arithmetic for a vial; peptide reconstitution volume calculations explains the method. Record the lot, the net mass used and the molecular weight assumed in the notebook, because a comparison between analogs is only as good as the molar matching.

Peptide content also matters. Purity by HPLC (the product page states ≥98%) describes the chromatographic profile, not the fraction of the vial that is peptide; counterions and residual water occupy mass. Where a certificate is published it appears in the COA library, and how to read a COA explains what each field means.

Handling points that apply to both

Both analogs are small proteins with disulfide bonds, and disulfide-containing proteins should not be exposed to reducing agents during preparation. Folding quality is a real variable in this family: the original fusion-analogue work emphasized refolding conditions that gave high yields of biologically active product (Francis 1992), and a vial that is misfolded or partly aggregated will under-report potency in any assay. The IGF-1 LR3 purity testing guide explains why a single HPLC peak does not prove correct folding.

For storage, the product page states refrigeration at 2–8 °C, −20 °C for long-term holding, and protection from heat, moisture and light. Once in solution, the usual rules apply: keep it cold, limit time in solution, divide into single-use portions, and avoid repeated freeze–thaw. General principles are in storing research peptides and how to reconstitute a lyophilized peptide. Low-protein-binding plastic is worth using for dilute solutions of a basic protein like IGF-1.

How to read analog potency claims

Be cautious with statements such as “LR3 is X times more potent than IGF-1.” The only defensible version names the cell type, the medium, the readout and the IGFBP content. In the cited L6 myoblast work, the potency gain of the truncated form appeared in a protein-synthesis assay but not in a competition-binding assay on the same cells (Ballard 1987). A gain that exists in one readout and not another is a clue about mechanism, and it is also a warning against extrapolating a single fold-change to every system.

It is equally worth remembering that the IGF system has a second receptor axis. IGF-1 signals mainly through the type 1 IGF receptor, and signaling downstream of the insulin and IGF receptors overlaps (Siddle 2011). If a readout could be driven by either receptor, include an inhibitor or a blocking-antibody arm so that the conclusion is attributed to the right receptor.

A short decision checklist

  • Write down which IGFBPs the medium and cells are expected to contain.
  • Choose native IGF-1 as the reference arm in every experiment that uses an analog.
  • Convert all concentrations to molar before comparing analogs.
  • Match lot, vial handling and freeze–thaw history across arms.
  • State the analog, medium and readout whenever a potency figure is quoted.
  • Confirm identity and purity from the certificate where one is published.

For more on the compound family see IGF-1 LR3 explained and sourcing criteria for IGF-1 LR3. The broader catalog is on the shop page. All material is for laboratory research use only; not for human or animal consumption.

Frequently asked questions

What is the difference between IGF-1 LR3 and des(1-3) IGF-1?

Des(1-3) IGF-1 is native IGF-1 minus its first three residues, giving 67 amino acids. IGF-1 LR3 has all residues, with Arg substituted for Glu at position 3 and a 13-residue N-terminal extension, giving 83 amino acids. Both bind IGFBPs less tightly than native IGF-1.

Which analog is better for cell culture?

Neither is universally better. Both help most in serum-containing or IGFBP-secreting systems. In a defined serum-free medium native IGF-1 may already suffice. Choose by medium, readout and control design, and keep native IGF-1 as a reference arm.

Does des(1-3) IGF-1 bind the IGF receptor more tightly?

In the cited L6 myoblast work the truncated form was about seven times more potent in a protein-synthesis assay but was not better at competing for IGF-1 binding to the cells, which points to reduced interference rather than higher receptor affinity (Ballard 1987).

Why do IGF-binding proteins matter in an assay?

They bind IGFs with high affinity and can sequester them away from the type 1 IGF receptor, inhibiting IGF-stimulated events, although matrix-associated IGFBPs can also concentrate IGFs near the receptor. The net effect depends on the cells and the medium.

Can I compare the two analogs by weight?

No. They differ in molecular weight, so equal masses are different molar amounts. Convert with n = m / MW and C = n / V, then compare at matched molar concentration.

Does the V8 catalog include des(1-3) IGF-1?

The product page covered here is for IGF-1 LR3, supplied as a 1 mg lyophilized powder with purity stated as ≥98% by HPLC. This article is a neutral comparison, not a statement about other catalog items.

How should IGF-1 LR3 be stored?

The product page states refrigeration at 2–8 °C, −20 °C for long-term storage, and protection from heat, moisture and light. Solutions should be kept cold and divided into single-use portions.

Is HPLC purity enough to judge an IGF analog?

It is necessary but not sufficient. A single chromatographic peak does not show correct disulfide folding or net peptide content, so identity and folding checks and a published certificate, where available, add information.

What control should accompany an analog experiment?

Native IGF-1 at matched molar concentration, a vehicle control, and where the receptor identity matters, an arm that blocks the type 1 IGF receptor so the signal can be attributed correctly.

Related reading: IGF-1 LR3 vs Standard IGF-1: Binding Proteins in Culture, IGF-1 LR3 Half-Life: What Published Studies Report, IGF-1 LR3 Mechanism of Action: Receptor Signaling.

References

  1. Ballard FJ, Francis GL, Ross M, Bagley CJ, May B, Wallace JC. Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding. Biochem Biophys Res Commun. 1987;149(2):398-404. doi:10.1016/0006-291X(87)90380-9
  2. Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhancing growth. J Mol Endocrinol. 1992;8(3):213-223. doi:10.1677/jme.0.0080213
  3. Bayne ML, et al. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor. J Biol Chem. 1988;263(13):6233-6239. doi:10.1016/S0021-9258(18)68777-0
  4. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278(6):E967-E976. doi:10.1152/ajpendo.2000.278.6.E967
  5. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824-854. doi:10.1210/er.2001-0033
  6. Clemmons DR. Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr Rev. 2001;22(6):800-817. doi:10.1210/edrv.22.6.0449
  7. Ross M, et al. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J. 1989;258(1):267-272. doi:10.1042/bj2580267
  8. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol. 2011;47(1):R1-R10. doi:10.1530/JME-11-0022

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.